ABBOTT LABORATORIES (ABT) Operating Margin
- Operating margin · 12 months: Value 17.07%; Formula and calculation Operating income / revenue. Period ending 2026-03-31..
Operating margin
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 17.07% | Operating income / revenue. Period ending 2026-03-31. $7.71B ÷ $45.13B × 100 ≈ 17.07% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 7.71B USD | Operating Income (Loss) |
| Revenue | 45.13B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 19.74B USD | Cost of Goods and Services Sold |
| Research and development | 2.99B USD | Research and Development Expense |
| Selling, general and administration | 13.01B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $7.71B | $45.13B | $19.74B | $2.99B | $13.01B | 17.07% |
| 2025-12-31 | $8.05B | $44.33B | $19.32B | $2.94B | $12.33B | 18.17% |
| 2025-09-30 | $7.71B | $43.84B | $19.34B | $2.96B | $12.11B | 17.59% |
| 2025-06-30 | $7.51B | $43.11B | $18.96B | $2.90B | $11.95B | 17.43% |
| 2025-03-31 | $7.13B | $42.34B | $18.71B | $2.88B | $11.80B | 16.84% |
| 2024-12-31 | $6.83B | $41.95B | $18.71B | $2.84B | $11.70B | 16.27% |
| 2024-09-30 | $6.69B | $41.22B | $18.32B | $2.79B | $11.51B | 16.24% |
| 2024-06-30 | $6.48B | $40.73B | $18.23B | $2.75B | $11.34B | 15.92% |
| 2024-03-31 | $6.36B | $40.33B | $18.11B | $2.77B | $11.15B | 15.76% |
| 2023-12-31 | $6.48B | $40.11B | $17.98B | $2.74B | $10.95B | 16.15% |
| 2023-09-30 | $6.00B | $39.96B | $18.01B | $2.77B | $11.20B | 15.02% |
| 2023-06-30 | $6.13B | $40.23B | $18.04B | $2.88B | $11.21B | 15.23% |
| 2023-03-31 | $6.96B | $41.51B | $18.49B | $2.85B | $11.22B | 16.77% |
| 2022-12-31 | $8.36B | $43.65B | $19.14B | $2.89B | $11.25B | 19.16% |
| 2022-09-30 | $9.44B | $45.03B | $19.32B | $2.92B | $11.32B | 20.95% |
| 2022-06-30 | $10.21B | $45.55B | $19.11B | $2.81B | $11.36B | 22.42% |
| 2022-03-31 | $9.23B | $44.51B | $19.12B | $2.79B | $11.33B | 20.73% |
| 2021-12-31 | $8.43B | $43.08B | $18.54B | $2.74B | $11.32B | 19.56% |
| 2021-09-30 | $8.48B | $42.31B | $18.26B | $2.68B | $10.85B | 20.04% |
| 2021-06-30 | $7.43B | $40.23B | $17.81B | $2.59B | $10.38B | 18.46% |
| 2021-03-31 | $6.71B | $37.34B | $16.12B | $2.50B | $9.93B | 17.97% |
| 2020-12-31 | $5.36B | $34.61B | $15.00B | $2.42B | $9.70B | 15.48% |
| 2020-09-30 | $4.31B | $32.22B | $13.94B | $2.32B | $9.54B | 13.39% |
| 2020-06-30 | $4.02B | $31.44B | $13.34B | $2.33B | $9.68B | 12.78% |
| 2020-03-31 | $4.55B | $32.09B | $13.35B | $2.35B | $9.84B | 14.18% |
| 2019-12-31 | $4.53B | $31.90B | $13.23B | $2.44B | $9.77B | 14.21% |
| 2019-09-30 | $4.31B | $31.36B | $12.99B | (m) | $9.71B | 13.74% |
| 2019-06-30 | $4.11B | $30.93B | $12.80B | (m) | $9.65B | 13.27% |
| 2019-03-31 | $3.78B | $30.72B | $12.80B | (m) | $9.68B | 12.31% |
| 2018-12-31 | $3.65B | $30.58B | $12.71B | (m) | $9.74B | 11.94% |
| 2018-09-30 | $3.30B | $30.40B | (m) | (m) | $9.80B | 10.85% |
| 2018-06-30 | $3.07B | $29.57B | (m) | (m) | $9.54B | 10.39% |
| 2018-03-31 | $2.58B | $28.45B | (m) | (m) | $9.22B | 9.06% |
| 2017-12-31 | $1.73B | $27.39B | (m) | (m) | $9.12B | 6.30% |
| 2017-09-30 | $1.98B | $25.13B | (m) | (m) | $8.26B | 7.89% |
| 2017-06-30 | $2.07B | $23.61B | (m) | (m) | $7.79B | 8.77% |
| 2017-03-31 | $2.46B | $22.30B | (m) | (m) | $7.40B | 11.03% |
| 2016-12-31 | $3.19B | $20.85B | (m) | (m) | $6.67B | 15.27% |
| 2016-09-30 | $3.05B | $20.71B | (m) | (m) | $6.72B | 14.74% |
| 2016-06-30 | $2.87B | $20.56B | (m) | (m) | $6.76B | 13.95% |
| 2016-03-31 | $2.78B | $20.39B | (m) | (m) | $6.75B | 13.64% |
| 2015-12-31 | $2.87B | $20.41B | (m) | (m) | $6.79B | 14.05% |
| 2015-09-30 | $2.88B | $20.57B | (m) | (m) | $6.80B | 14.00% |
| 2015-06-30 | $2.90B | $20.50B | (m) | (m) | $6.72B | 14.13% |
| 2015-03-31 | $2.84B | $20.39B | (m) | (m) | $6.65B | 13.95% |
| 2014-12-31 | $2.60B | $20.25B | (m) | (m) | $6.53B | 12.84% |
| 2014-09-30 | $2.90B | $22.16B | (m) | (m) | $6.99B | 13.07% |
| 2014-06-30 | $2.60B | $21.82B | (m) | (m) | $6.99B | 11.91% |
| 2014-03-31 | $2.46B | $21.71B | (m) | (m) | $6.91B | 11.35% |
| 2013-12-31 | $2.63B | $21.85B | (m) | (m) | $6.94B | 12.03% |
| 2013-09-30 | $8.57B | $40.21B | (m) | (m) | $11.72B | 21.32% |
| 2013-06-30 | $8.25B | $40.10B | (m) | (m) | $11.90B | 20.58% |
| 2013-03-31 | $8.19B | $39.97B | (m) | (m) | $12.00B | 20.49% |
| 2012-12-31 | $8.08B | $39.87B | (m) | (m) | $12.06B | 20.28% |
| 2012-09-30 | $7.75B | $39.41B | (m) | (m) | $11.77B | 19.67% |
| 2012-06-30 | $6.36B | $39.46B | (m) | (m) | $13.09B | 16.11% |
| 2012-03-31 | $6.03B | $39.27B | (m) | (m) | $12.91B | 15.35% |
| 2011-12-31 | $5.75B | $38.85B | (m) | (m) | $12.76B | 14.81% |
| 2011-09-30 | $5.50B | $38.44B | (m) | (m) | $12.65B | 14.31% |
| 2011-06-30 | $6.09B | $37.30B | (m) | (m) | $11.08B | 16.32% |
| 2011-03-31 | $5.92B | $36.51B | (m) | (m) | $11.06B | 16.21% |
| 2010-12-31 | $6.09B | $35.17B | (m) | (m) | $10.38B | 17.31% |
| 2010-09-30 | $6.12B | $33.99B | (m) | (m) | $9.80B | 18.01% |
| 2010-06-30 | $6.58B | $33.08B | (m) | (m) | $9.22B | 19.89% |
| 2010-03-31 | $6.65B | $31.74B | (m) | (m) | $8.50B | 20.93% |
| 2009-12-31 | $6.24B | $30.76B | (m) | (m) | $8.41B | 20.27% |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $5.69B | $29.53B | (m) | (m) | $8.44B | 19.28% |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | $4.58B | $25.91B | (m) | (m) | $7.41B | 17.67% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |